We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Breath Ammonia Biomarker Predicts Kidney Function in CKD Patients

By LabMedica International staff writers
Posted on 18 Nov 2020
Chronic kidney disease (CKD) is a type of kidney disease in which there is gradual loss of kidney function over a period of months to years. More...
Initially there are generally no symptoms; later, symptoms may include leg swelling, feeling tired, vomiting, loss of appetite, and confusion.

Diagnosis of CKD is largely based on history, examination and urine dipstick combined with the measurement of the serum creatinine level. It is important to differentiate CKD from acute kidney injury (AKI) because AKI can be reversible. One diagnostic clue that helps differentiate CKD from AKI is a gradual rise in serum creatinine (over several months or years) as opposed to a sudden increase in the serum creatinine (several days to weeks).

Nephrologists at the Chang Gung Kidney Research Center (Taoyan, Taiwan) and their colleagues investigated whether exhaled breath ammonia measurement could be used for rapid CKD screening. The scientists enrolled 121 patients with CKD stages 1 to 5 (average age, 61 years; 62 patients were men) and compared breath ammonia level measurements with blood urea nitrogen (BUN), creatine and eGFR levels. The gas measurement system used in this study was composed of a rotameter, pump, desiccation cylinder, the sensing chamber, and an electrical signal measurement instrument (Keysight Technologies, Santa Rosa, CA, USA).

The team reported that breath ammonia level correlated with BUN, serum creatinine, eGFR and inversed eGFR levels. Breath ammonia concentration was increasingly elevated at each stage of CKD (stage 1: 636 ± 94 ppb; stage 2: 1,020 ± 326 ppb; stage 3: 1,943 ± 326 ppb; stage 4: 4,421 ± 1,042 ppb; stage 5: 12,781 ± 1,807 ppb). The area under curve for a breath ammonia level cutoff concentration of 1,187 ppb comparing patients with eGFR of at least 60 mL/min/1.73 m2 with patients with eGFR of no more than 60 mL/min/1.73 m2 was 0.831 (positive predictive value, 0.84; negative predictive value, 0.61; sensitivity, 71%; specificity, 78%).

The scientists noted that at 886 ppb, the sensitivity increased to 80%, but the specificity decreased to 69%. They also wrote there were no significant differences between patients in each stage regarding sex, body weight, hemoglobin, albumin, comorbidities and medication and that BUN level, creatinine and eGFR increased with each CKD stage.

Ya-chung Tian, MD, an associate professor of nephrology and a co-author of the study, said, “Because CKD is non-life threating and breath ammonia detection was conducted in real time, inexpensive, easy to administer and had an acceptable diagnostic accuracy, breath ammonia can be used as a good surrogate for kidney function and a reliable tool for CKD screening.”

The authors concluded that breath ammonia detection with vertical-channel organic semiconductor (V-OSC) is a real time, inexpensive, and easy to administer measurement device for screening CKD with reliable diagnostic accuracy. The study was published on October 31, 2020 in the journal Biomedical Materials and Nanomedicine.

Related Links:
Chang Gung Kidney Research Center
Keysight Technologies



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
New
Automated Microscope
dIFine
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.